CytoMed Therapeutics (GDTC) Non-Current Debt (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Non-Current Debt for 5 consecutive years, with $284446.8 as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 4.04% to $284446.8 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $284446.8 through Dec 2025, down 4.04% year-over-year, with the annual reading at $286691.0 for FY2025, 0.67% down from the prior year.
  • Non-Current Debt hit $284446.8 in Q4 2025 for CytoMed Therapeutics, down from $296433.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $397270.9 in Q4 2021 to a low of $284446.8 in Q4 2025.
  • Historically, Non-Current Debt has averaged $323600.6 across 5 years, with a median of $302033.6 in 2023.
  • Biggest five-year swings in Non-Current Debt: decreased 14.97% in 2022 and later dropped 1.85% in 2024.
  • Year by year, Non-Current Debt stood at $397270.9 in 2021, then fell by 14.97% to $337818.9 in 2022, then dropped by 10.59% to $302033.6 in 2023, then fell by 1.85% to $296433.0 in 2024, then decreased by 4.04% to $284446.8 in 2025.
  • Business Quant data shows Non-Current Debt for GDTC at $284446.8 in Q4 2025, $296433.0 in Q4 2024, and $302033.6 in Q4 2023.